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Complete histologic normalisation is associated with reduced 
risk of relapse among patients with ulcerative colitis in 
complete endoscopic remission





























Background: Clinical	 and	 endoscopic	 remission	 are	 treatment	 targets	 in	 ulcera‐
tive	colitis	(UC).	The	value	of	histologic	healing	in	altering	clinical	outcomes	among	 
patients	with	complete	endoscopic	healing	is	not	well	established.
Aim: To	 quantify	 the	 association	 between	 histologic	 activity	 and	 clinical	 relapse	
among	patients	with	UC	who	were	in	complete	endoscopic	remission.

















































activity	using	 various	definitions	 and/or	did	not	utilise	 a	 validated	
histologic	activity	score.17,19	Thus,	whether	histologic	normalisation	














area.	 To	 be	 eligible	 for	 inclusion,	 patients	 were	 required	 to	 meet	
the	 following	criteria:	 (a)	 established	diagnosis	of	UC	according	 to	
standard	diagnosis	criteria;	(b)	enrolment	in	the	prospective	institu‐
tional	 registry;	 (c)	a	colonoscopy	with	complete	endoscopic	 remis‐
sion	defined	as	a	Baron	score	of	0	(normal	mucosa	with	no	erythema	
or	 friability)24;	 and	 (d)	 clinical	 follow‐up	 of	 2	 years.	 Of	 all	 eligible	 




endoscopic	and	histologic	 remission	and	 is	 likely	 from	non‐inflam‐
matory	changes.25
2.2 | Clinical covariates and outcome of interest
The	primary	outcome	was	clinical	relapse	within	two	years	from	the	
time	of	 the	 index	colonoscopy.	This	was	defined	as	any	change	 in	
UC	 therapy	 (ie	dose	escalation,	 class	 change	and/or	need	 for	 sys‐
temic	 corticosteroids),	 UC‐related	 hospitalisation	 or	 UC‐related	
surgery	within	2	years.	Only	dose	change	or	medication	alterations	
for	symptomatic	exacerbations	of	disease	with	clinical	suspicion	for	










and	 depression	 scores	 as	 measured	 using	 the	 Patient‐Reported	
Outcomes	 Measurement	 Information	 System	 (PROMIS)	 question‐
naires.	Current	immune	modulator	use	was	recorded	for	either	thio‐
purine	 (azathioprine,	 6‐mercaptopurine)	 or	 methotrexate	 therapy.	
Current	biologic	use	was	recorded	for	either	tumour	necrosis	factor	
α	 antagonists	 (infliximab,	 adalimumab,	 golimumab)	 or	 anti‐integrin	
(vedolizumab)	therapy.
2.3 | Assessment of histologic activity
All	histologic	specimens	from	the	index	colonoscopy	were	reviewed	
by	a	single	senior	gastrointestinal	pathologist	(VD)	who	was	blinded	
to	 the	 outcome	 of	 interest.	 The	 site	 with	 the	 most	 histologically	 
active	 disease	 was	 scored	 according	 the	 Geboes	 score.27 The in‐
dividual	components	of	 the	Geboes	score	were	 recorded	 for	each	
patient:	structural	 (architectural	change)	 (Grade	0),	chronic	 inflam‐
matory	 infiltrate	 (Grade	1),	 lamina	propria	 eosinophils	 (Grade	2A),	
lamina	 propria	 neutrophils	 (Grade	 2B),	 neutrophils	 in	 the	 epithe‐
lium	 (Grade	3),	 crypt	destruction	 (Grade	4)	 and	erosion	or	 ulcera‐
tion	 (Grade	5).27	The	expected	 lymphoplasmacytic	 infiltrate	 in	 the	
colonic	segment	chosen	for	review	was	accounted	for	when	scoring	
the	grade	“chronic	inflammatory	infiltrate”.	We	modelled	histologic	
activity	 as	 a	 predictor	 variable	using	 three	definitions.28	 First,	 pa‐
tients	were	 classified	 as	 having	 histologically	 active	 disease	 if	 the	



















The	 study	 was	 approved	 by	 the	 Institutional	 Review	 Board	 of	
Partners	 Healthcare.	 All	 patients	 provided	 informed	 consent.	
Categorical	 variables	 are	 presented	 as	 counts	 and	 percentages.	
Comparisons	between	categorical	 variables	were	performed	using	
the	chi‐squared	test	or	Fisher	exact	test,	as	appropriate.	Continuous	
variables	 are	 presented	 as	 means	 ±	 standard	 deviations	 or	 medi‐
ans	±	interquartile	ranges	based	on	normal	distribution	of	the	vari‐




cant	 in	 this	analysis	at	P	<	0.05	or	 those	that	had	been	previously	
determined	to	be	 important	 in	predicting	relapse	were	 included	 in	
a	 final	multivariable	model	 that	 examined	 the	 independent	 effect	
of	histologic	changes.	A	two‐sided	P < 0.05 indicated independent 
statistical	 significance.	A	 receiver	operating	curve	 (ROC)	was	con‐
structed	for	the	final	model	and	the	area	under	the	curve	(AUC)	was	
calculated.	We	 repeated	 the	analysis	using	Cox	 regression	models	
and	 plotted	 a	 Kaplan‐Meier	 curve	 of	 time	 to	 relapse	 stratifying	
by	 histologic	 normalisation	 or	 activity.	 Analysis	 were	 performed	
in	R	 (version	3.5.3)	using	RStudio,	 version	1.1.456,	 and	Stata	13.2	







Most	 patients	 had	 pancolitis	 (55%)	with	 66%	 exposed	 to	 immune	








complete	 endoscopic	 remission	 (endoscopic	 subscore	 of	 0)	 dem‐
onstrated	 complete	 histologic	 normalisation	 by	 the	 Geboes	 score	
(n	=	41,	49%).	A	total	of	20	patients	(24%)	and	27	patients	(33%)	met	
the	criteria	for	histologically	active	disease	defined	using	a	Geboes	






lapsed,	 one	 required	 surgery,	 three	 required	 hospitalisation	 for	 a	
flare	 of	 their	UC,	 16	were	 initiated	on	 systemic	 steroids,	 11	were	
started	on	 topical	 therapy,	 four	 required	new	 initiation	of	biologic	
therapy,	three	changed	their	biologic	agent	due	to	loss	of	response	
and	 two	 additionally	 had	 a	 dose	 increase	 of	 thiopurine.	Only	 two	
patients	 de‐escalated	 therapy	 after	 the	 index	 colonoscopy—one	
stopped	mesalazine	 (mesalamine)	and	 the	other	 stopped	anti‐TNF.	
Both	relapsed	of	which	one	had	complete	histologic	normalisation	at	
baseline	while	the	other	had	histologically	active	disease.	Exclusion	
of	 these	 two	patients	 from	 the	analysis	did	not	alter	our	 findings.	
Clinical	 symptoms,	 defined	 as	 an	 SCCAI	 ≥2,	 were	 present	 in	 19	
of	 81	 patients	 assessed	 at	 the	 time	 of	 colonoscopy	 (23%)	 despite	
complete	 endoscopic	 remission.	 Patients	who	 experienced	 clinical	
relapse	within	two	years	of	histologic	evaluation	were	similar	in	de‐
mographic	 characteristics	 compared	 to	 those	who	did	not	 relapse	
(Table	1).	Age	at	diagnosis	(27	vs	25	years,	P	=	0.78),	disease	dura‐
tion	(14	vs	10	years,	P	=	0.11),	gender	(P	=	0.34)	and	race/ethnicity	




3.2 | Histologic changes and relapse
Patients	 with	 complete	 histologic	 normalisation	 by	 the	 Geboes	
score	 were	 less	 likely	 to	 experience	 relapse	 (12%)	 compared	 to	
those	without	 (50%,	P	<	0.001)	 (Figure	1).	 In	contrast,	histologic	
activity	 as	 assessed	 by	 a	 Geboes	 score	 of	 ≥2.1a	 (44%	 vs	 25%,	
P	 =	 0.12),	 ≥2.1b	 (38%	vs	 29%,	P	 =	 0.62)	 and	≥3.1	 (40%	vs	 28%,	
P	 =	 0.49)	 was	 not	 significantly	 associated	 with	 risk	 of	 relapse	
(Table	2).	However,	the	percentage	of	patients	with	clinical	relapse	
was	higher	in	all	groups	with	higher	Geboes	scores	(Figure	2).	Two	
subcomponents	 of	 the	 Geboes	 score	 demonstrated	 significant	
associations	with	 risk	of	clinical	 relapse	within	2	years	 (Table	3).	
The	strongest	association	was	observed	with	the	presence	of	in‐
creased	 numbers	 of	 chronic	 inflammatory	 cells	 (P	 <	 0.001)	with	




infiltrate	 (65%).	 The	 second	 significant	 association	 with	 clini‐










Kaplan‐Meier	 survival	 curve	 describing	 time	 to	 relapse	 similarly	
demonstrated	 a	 lower	 frequency	 of,	 and	 longer	 time	 to,	 relapse	
among	 those	 achieving	 complete	 histologic	 normalisation	 (log‐
rank	P	=	0.0002)	but	not	when	stratifying	by	histologic	activity	at	
a	cut‐off	of	Geboes	3.1	(P	=	0.52)	(Figure	3).
3.3 | Multivariable predictors of relapse
Lack	 of	 complete	 histologic	 normalisation	 by	 the	 Geboes	 score	








3.4 | Predictive models using the Robarts Histologic 















lapse (n = 26)
No clinical re-
lapse (n = 57) P value
Age	at	diagnosis 27.5	±	15.3 25	±	20 0.78
Age	at	visit 44.5	±	19.3 43	±	23 0.57
Disease	duration 14.5	±	12 10	±	9 0.11
Gender
Male 10	(38.4%) 30	(52.6%) 0.34
Female 16	(61.5%) 27	(47.4%)  
Race
White 24	(92.3%) 55	(96.5%) 0.59* 
Non‐white 2	(7.7%) 2	(3.5%)  
Pancolitis
Yes 14	(53.8%) 32	(56.1%) 1.00
No 12	(46.2%) 25	(43.9%)  
Current	immune	modulator
Yes 11	(42.3%) 23	(40.4%) 1.00
No 15	(57.7%) 34	(59.6%)  
Current	biologic
Yes 7	(26.9%) 21	(36.8%) 0.52
No 19	(73.1%) 36	(63.2%)  
Current	steroid
Yes 2	(7.7%) 2	(3.5%) 0.59* 
No 24	(92.3%) 55	(96.5%)  
*Fisher's	exact	test.	
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not	 reveal	 any	 significant	 associations	 between	 RHI	 and	 risk	 of	
relapse.
3.5 | Association between histologic changes and 
disease symptoms





when	 histologic	 activity	was	 defined	 as	 a	 Geboes	 score	 of	 ≥	 3.1,	
there	was	no	difference	 in	faecal	urgency	(20%	vs	35%,	P	=	0.27),	
general	well‐being	(15%	vs	27%,	P	=	0.37),	blood	in	the	stool	(15%	








endoscopic	 inflammatory	 activity	 even	 in	 the	 absence	 of	 symp‐
toms	 is	 associated	with	worse	 long‐term	outcomes.4‐6	However,	
the	recognition	that	histologic	activity	persists	even	in	a	significant	
subset	of	patients	with	complete	endoscopic	normalisation	has	led	





attempted	 to	 define	 the	 optimal	 histologic	 target	 necessary	 for	
modifying	future	disease	course	and	whether	this	differs	from	that	





tive	 inflammatory	 infiltrate	 was	 associated	 with	 reduced	 future	
risk	 of	 relapse.	 These	 results	 may	 suggest	 incremental	 benefit	
in	 attaining	 histologic	 remission	 in	 UC	 and	 further	 suggest	 that	









No clinical relapse 
(n = 57) P value
Lack	of	normalisation	(Geboes	>	0)
Yes 21	(50%) 21	(50%) <0.001
No 5	(12%) 36	(88%)  
Geboes	≥	2.1a
Yes 12	(44%) 15	(56%) 0.12
No 14	(25%) 42	(75%)  
Geboes	≥	2.1b
Yes 8	(38%) 13	(62%) 0.62
No 18	(29%) 44	(71%)  
Geboes	≥	3.1
Yes 8	(40%) 12	(60%) 0.49
No 18	(28%) 45	(72%)  














































































P = 0.12 P = 0.62 P = 0.49
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to	clinicians	when	faced	with	a	discrepancy	between	histologic	ac‐
tivity	and	endoscopic	remission,	there	are	still	insufficient	data	to	
recommend	 histologic	 healing	 as	 a	 necessary	 therapeutic	 target	
in	all	patients.
A	few	prior	studies	have	evaluated	the	impact	of	histologic	dis‐
ease	activity	on	clinical	outcomes	 in	UC.	A	 large	 retrospective	co‐
hort	by	Christensen	et al	demonstrated	that	histologic	normalisation	
was	beneficial	even	 in	 those	with	endoscopic	 remission,	but	histo‐















patients	 in	 complete	endoscopic	 remission	 and	expands	 the	histo‐
logical	analysis	to	include	derived	RHI	and	Nancy	histology	indices.
A	systematic	 review	and	meta‐analysis	performed	 in	2016	 in‐
vestigated	the	available	data	in	this	area	to	determine	the	associ‐
ation	between	histologic	healing	and	relapse.14	The	authors	found	
that	 histologic	 remission	was	 associated	with	 reduced	 risk	 of	 re‐
lapse	 (relative	 risk	 0.48).	 Furthermore,	 absence	 of	 neutrophils	 in	
the	 epithelium,	 neutrophils	 or	 eosinophils	 in	 the	 lamina	 propria,	
crypt	 abscesses	and	chronic	 inflammatory	 cell	 infiltrates	were	all	
associated	with	 lower	 risk	 of	 clinical	 relapse.	One	explanation	of	
the	 heterogeneity	 in	 previous	 findings	 including	 association	 be‐
tween	histologic	remission	and	relapse	in	prior	studies	is	inclusion	
of	patients	with	endoscopic	score	0	or	1.	However,	one	limitation	
of	 this	 analysis	 is	pooling	 together	of	patients	 across	a	 spectrum	
of	endoscopic	activity.	Patients	with	an	endoscopic	subscore	of	1	















(n = 57) P value
Structural	(architectural	change)   0.03
No	abnormality 16	(61.5%) 49	(86%)  
Mild	Abnormality 8	(30.8%) 6	(10.5%)  
Mild	or	moderate	diffuse	or	
multifocal	abnormalities
2	(7.7%) 2	(3.5%)  
Severe	diffuse	or	multifocal	
abnormalities
0 0  
Chronic	inflammatory	infiltrate   <0.001* 
No	increase 5	(19.2%) 37	(64.9%)  
Mild	but	unequivocal	increase 17	(65.4%) 13	(22.8%)  
Moderate	increase 4	(15.4%) 3	(5.3%)  
Marked	increase 0 4	(7%)  
Lamina	Propria	neutrophils	and	
eosinophils
   
2	A:	Eosinophils   0.08* 
No	increase 16	(61.5%) 47	(82.4%)  
Mild but unequivocal 
increase
7	(26.9%) 9	(15.8%)  
Moderate	increase 1	(3.8%) 0  
Marked	increase 2	(7.7%) 1	(1.8%)  
2B:	Neutrophils   0.69* 
None 26	(100%) 53	(93%)  
Mild but unequivocal 
increase
0 3	(5.3%)  
Moderate	increase 0 1	(1.7%)  
Marked	increase 0 0  
Neutrophils	in	the	epithelium   0.35* 
None 18	(69.2%) 45	(78.9%)  
<5%	crypts	involved 6	(23.1%) 6	(10.5%)  
<50%	crypts	involved 1	(3.8%) 5	(8.8%)  
>50%	crypts	involved 1	(3.8%) 1	(1.8%)  
Crypt	destruction   0.59* 
None 24	(92.3%) 55	(96.5%)  
Probable—local	excess	of	
neutrophils	in	part	of	crypt
2	(7.7%) 2	(3.5%)  
Probably—marked	attenuation 0 0  
Unequivocal	crypt	
destruction
0 0  
Erosion	or	Ulceration   N/A
No	erosion,	ulceration,	or	
granulation	tissue
26	(100%) 57	(100%)  
Recovering	epithelium	+	
adjacent	inflammation
0 0  
Probable	erosion—focally	
stripped








(n = 57) P value
Unequivocal	erosion 0 0  
Ulcer	or	granulation	tissue 0 0  
*Fisher's	Exact	test.	
TA B L E  3   (Continued)






















for	 observer	 bias.	 Third,	we	 used	 the	Geboes	 score	 for	 primary	
histologic	assessment	but	also	 included	RHI	and	Robarts.	To	our	
knowledge,	 ours	 is	 the	 first	 study	 to	 simultaneously	 examine	 all	
three	 scoring	 systems	 to	 predict	 relapse.	 The	Geboes	 score	 is	 a	
comprehensive	 histologic	 scoring	 system	 which	 evaluates	 both	
acute	 and	 chronic	 inflammatory	 changes	 in	 addition	 to	 architec‐
tural	 distortion.	 This	 score	 has	 been	 shown	 to	 have	 good	 con‐










We	 readily	 acknowledge	 some	 limitations	 of	 this	 work.	 First,	
there	 was	 a	 relatively	 small	 sample	 size	 which	 may	 have	 limited	
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TA B L E  4  Multivariable	logistic	regression	evaluating	predictors	
of	clinical	relapse	at	2	years




Disease	duration 1.03 0.97‐1.08 0.38
Current	biologic	use 0.75 0.24‐2.28 0.68
Age	at	visit 0.99 0.96‐1.04 0.93
aComplete	histologic	normalisation	indicates	a	Geboes	score	of	0.	
















































atic	 flares.	Overall,	 the	 small	 sample	 size,	 small	 event	 rate	 in	 the	
Geboes	0	group	and	retrospective	nature	of	the	design	are	import‐
ant	 limitations	 of	 this	 study.	However,	 this	work	 offers	 the	most	








the	 ability	 to	 achieve	 deeper	 remission	 with	 complete	 histologic	
healing	may	 not	 be	 achievable	 in	 all	 patients.37,42,43	Our	 findings	
highlight	 the	 importance	 of	 consensus	 definitions	 across	 studies	
regarding	the	definition	of	histologic	remission	and	establishment	
of	 relevant	 cut‐offs	 not	 just	 for	 therapeutic	 response	 but	 also	 to	
modify	long‐term	history	of	disease	to	optimise	patient	outcomes.
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